湿润烧伤膏治疗皮肤擦伤的临床效果观察

目的 观察湿润烧伤膏治疗皮肤擦伤的临床效果。方法 选取2011年1月~2013年1月在本院门诊和外科治疗皮肤擦伤的患者304例,按治疗方法不同分为治疗组和对照组,治疗组采用湿润烧伤膏治疗,对照组采用传统方法治疗,观察两组的治疗效果。结果 治疗组的止痛时间为（1.0±0.5）h,治愈天数为（12.24±2.64）d,创面感染率为5.13%,愈合瘢痕形成率为7.69%,色素沉着率为11.54%,与对照组比较,差异有统计学意义（P〈0.01）。结论 湿润烧伤膏治疗皮肤擦伤取得了良好的效果,无任何刺激性和副作用,操作简单,使用方便,特别适合基层医院应用。     

聚维酮碘联合湿润烧伤膏治疗Ⅱ度烧伤创面62例

目的：探讨聚维酮碘联合湿润烧伤膏治疗Ⅱ度烧伤创面的临床体会。方法：采用回顾性分析方法,分析东莞市万江医院收治的245例Ⅱ度烧伤患者,依据治疗方式的不同及自身对照方法分为4组,观察组（A组）、对照组（B组）、自身对照的观察组（C组）和自身对照的对照组（D组）,A组62例聚维酮联合湿润烧伤膏治疗,B组73例只用湿润烧伤膏治疗。结果：Ⅱ度烧伤创面平均愈合时间及感染率,A组优于B组（P〈0.05）、C组优于D组（P〈0.05）;用药治疗后止痛效果及换药时疼痛程度,A组与B组、C组与D组无明显差异。结论：湿润烧伤膏为创面提供了仿生理湿润环境,可促进创面愈合,具有止痛及减少瘢痕形成作用,但抗感染作用不强,联合聚维酮碘使用,创面感染率明显降低,愈合时间缩短,效果明显,值得临床推广。     

磺胺嘧啶锌软膏、美宝湿润烧伤膏与重组人表皮生长因子凝胶混合治疗烧伤创面疗效观察

目的观察磺胺嘧啶锌软膏、美宝湿润烧伤膏与重组人表皮生长因子凝胶混合治疗Ⅱ度烧伤创面的疗效。方法 380例烧伤患者,烧伤深度在浅Ⅱ度至深Ⅱ度之间,创面大小为1%~35%,随机分两组,治疗组260例予以磺胺嘧啶锌软膏、美宝湿润烧伤膏与重组人表皮生长因子凝胶混合治疗;对照组120例应用八湿膏药纱治疗。同时全身给予必要的营养支持及辅助治疗。结果患者创面在外敷磺胺嘧啶锌软膏、湿润烧伤膏与重组人表皮生长因子凝胶混合后30min疼痛减轻,浅Ⅱ度在用药后8.0±2.0d愈合,深Ⅱ度在用药后16±2.0d愈合,创面基本愈合,2例植皮,出院随访的深Ⅱ度创面愈合后增生瘢痕有不同程度的减轻。结论磺胺嘧啶锌软膏、湿润烧伤膏与重组人表皮生长因子凝胶混合可以促进Ⅱ度烧伤创面愈合,操作简便,疗效可靠,对深Ⅱ度创面的治疗对防止瘢痕增生的有一定的功效。     

美宝湿润烧伤膏与磺胺嘧啶银治疗烧伤的疗效比较

目的观察美宝湿润烧伤膏与磺胺嘧啶银治疗烧伤创面的疗效。方法将80例Ⅱ度烧伤患者随机分为2组,治疗组（40例）用美宝湿润烧伤膏涂于创面,对照组（40例）用磺胺嘧啶银涂于创面,观察2组的止痛效果、创面炎症控制、创面愈合时间及换药次数。结果治疗组止痛总有效率为90.0%显著高于对照组的27.5%,差异有统计学意义（P〈0.01）;换药后创面炎症控制方面对照组优于治疗组（P〈0.05）;换药次数,治疗组明显多于对照组（P〈0.05）;创面愈合时间：治疗组多于对照组（P〈0.05）。结论美宝湿润烧伤膏在止痛效果、减轻瘢痕发生率方面优于磺胺嘧啶银,磺胺嘧啶银在预防、控制创面感染,加快深度烧伤创面愈合等方面优于湿润烧伤膏。     

苏肤凝胶在烧烫伤换药中的疗效观察及应用

目的:观察苏肤凝胶在烧烫伤换药中的效果。方法:患者均为Ⅱ度烧烫伤及深Ⅱ度烧烫伤所导致的创面共96例,随机分为治疗组48例,对照组48例。治疗组使用为生理盐水消毒伤口后再在伤口上涂抹苏肤凝胶(医用壳聚糖创面修复膜凝胶)进行伤口换药,对照组使用为生理盐水消毒伤口后再在伤口上涂抹磺胺嘧啶银进行伤口换药,观察并同时记录两组患者在伤口换药后的伤口愈合时间、换药伤口疼痛的情况。结果:治疗组的愈合时间明显短于对照组(P<0.01),治疗组伤口换药疼痛程度明显低于对照组(P<0.01)。结论:苏肤应用于Ⅱ度烧烫伤及深Ⅱ度烧烫伤创面的换药中,有较好的促进创面修复作用,止痛效果好,清除余热快,可为创面提供生理湿润环境,减少瘢痕形成等功效,能有效缩短烧伤创面的愈合时间。     

美宝湿润烧伤膏与磺胺嘧啶银霜治疗大面积烧伤疗效比较

目的比较美宝湿润烧伤膏与磺胺嘧啶银霜治疗大面积烧伤的疗效。方法将我院2006年6月至2010年6月收治的240例烧伤面积在35%～86%的患者随机分为观察组和对照组,每组120例,对照组采用磺胺嘧啶银霜治疗,观察组采用美宝湿润烧伤膏治疗,比较两组患者的细菌感染率,创面愈合时间,手术植皮率,休克期补液量和尿量,瘢痕发生率,第7天时高热症状例数以及毒副作用。结果观察组细菌感染率、手术植皮率、瘢痕发生率、第7d时高热症状例数以及毒副作用显著少于对照组,P<0.05。且观察组休克期补液量显著少于、尿量显著多于对照组,P<0.05。结论美宝湿润烧伤膏治疗大面积烧伤疗效较好,能迅速促进创面愈合,且毒副作用少。     

美宝湿润烧伤膏治疗烧烫伤57例临床观察

目的探讨美宝湿润烧伤膏治疗烧烫伤的临床药疗观察。方法选取2001至2009年二道江区第二人民医院烫伤患者57例,使用美宝湿润烧伤膏进行治疗,并对此进行疗效观察。结果 48例浅Ⅱ0,7~9天全部愈合。深Ⅱ0浅Ⅱ0,12天~15天也相继结痂褪痂中,用药期间创面无感染迹象,褪痂后的皮肤色泽粉红,追踪观察,四周后创面部分区域有浅褐色素沉着,皮肤光滑无突起和瘢痕。用药期间创面保持湿润状态,疼痛不明显。肿胀明显消退,渗出期缩短,渗出明显减少。结论应用美宝湿润烧伤膏治疗烧烫伤取得良好疗效,值得临床推广。     

湿润烧伤膏治疗复发性肛瘘术后创面的临床疗效观察

目的:观察湿润烧伤膏治疗复发性肛瘘术后创面的临床疗效.方法:89例复发性肛瘘患者随机分为对照组和观察组,对照组术后创面采用常规方式治疗,观察组术后采用湿润烧伤膏进行治疗.观察疗效.结果:观察组的治疗有效率达97.78%优于对照组的86.36%,P<0.05;观察组的创面恢复时间(4.5±0.3d)优于对照组(6.1±0.8d),P<0.05.观察组各阶段疼痛分值均低于对照组P<0.05.结论:湿润烧伤膏治疗复发性肛瘘术后创面疗效确切,具有临床药用价值.     

烧伤油膏临床适应性观察

目的观察烧伤油膏对烧烫伤的临床疗效。方法将100例烧烫伤患者,随机分为治疗组和对照组,每组50例,治疗组选用自制烧伤油膏外涂局部创面,对照组选用外涂湿润烧伤膏外涂局部创面,观察比较两组临床疗效。结果使用自制烧伤油膏的治疗组在痊愈时间方面优于使用湿润烧伤膏的对照组,平均治疗时间比较差异有统计学意义(P<0.05)。结论自制烧伤油膏治疗Ⅰ、Ⅱ度烧烫伤的疗效优于湿润烧伤膏方法,无明显副作用,疗程短,效果良好。     

术尔泰与湿润烧伤膏治疗烧伤的疗效比较

目的 比较术尔泰与湿润烧伤膏治疗烧伤的临床疗效.方法 120例烧伤患者按随机数字表法分为观察组和对照组各60例.对照组采用湿润烧伤膏涂抹,观察组采用术尔泰外敷.观察两组临床疗效、创面愈合时间和创面感染率.结果 观察组显效率为75.0%（45160）,对照组为50.0%（30/60）,差异有统计学意义（Х^2=8.00,P＜0.01）;观察组总有效率为98.3%（59/60）,对照组为95.0%（57/60）,差异无统计学意义（Х^2=0.26,P＞0.05）;观察组创面愈合时间明显短于对照组,创面感染率明显低于对照组,差异均有统计学意义（均P＜0.05）.结论 相比湿润烧伤膏,术尔泰疗效显著,愈合时间快,感染率低,值得临床推广应用.     

Nachweis einiger Heilmittel in der Kniegelenksynovialflüssigkeit

Zusammenfassung Mittels Gaschromatographie und Dünschichtchromatographie wiesen die Autoren 11 Substanzen nach, welche durch Injektion oder nach Verabreichung per os in die Kniegelenksynovialflüssigkeit eindrangen. In ihrer Aufstellung konnten sie eine direkte Beziehung zwischen Struktur sowie chemischphysikalischen Eigenschaften der Substanz und ihrer Fähigkeit, aus dem Blut in die Kniegelenksynovialflüssigkeit einzudringen, nicht nachweisen, außer der Tatsache, daß Substanzen mit starker Affinität zu Eiweißstoffen erst in höheren Dosen nachweisbar waren.     

Synthesis,Cytotoxicity and Antileishmanial Activity of Some N-(2-(indol-3-yl)ethyl)-7-chloroquinolin-4-amines

We report herein the condensation of 4,7-dichloroquinoline (1) with tryptamine (2) and D-tryptophan methyl ester (3) . Hydrolysis of the methyl ester adduct (5) yielded the free acid (6) . The compounds were evaluated in vitro for activity against four different species of Leishmania promastigote forms and for cytotoxic activity against Kb and Vero cells. Compound (5) showed good activity against the Leishmania species tested, while all three compounds displayed moderate activity in both Kb and Vero cells.     

Emerging drugs for epilepsy

Epilepsy affects ≤ 1% of the world's population. Antiepileptic drugs (AEDs) are the mainstay of treatment, although more than a third of patients are not rendered seizure free with existing medications. Uncontrolled epilepsy is associated with increased mortality and physical injuries, and a range of psychosocial morbidities, posing a substantial economic burden on individuals and society. Limitations of the present AEDs include suboptimal efficacy and their association with a host of adverse reactions. Continued efforts are being made in drug development to overcome these shortcomings employing a range of strategies, including modification of the structure of existing drugs, targeting novel molecular substrates and non-mechanism-based drug screening of compounds in traditional and newer animal models. This article reviews the need for new treatments and discusses some of the emerging compounds that have entered clinical development. The ultimate goal is to develop novel agents that can prevent the occurrence of seizures and the progression of epilepsy in at risk individuals.     

盐酸达泊西汀中甲磺酸甲酯、甲磺酸乙酯及甲磺酸异丙酯的顶空毛细管GC-ECD法测定

建立了衍生化顶空毛细管气相色谱-电子捕获检测器(ECD)法测定盐酸达泊西汀中的甲磺酸甲酯(MMS)、甲磺酸乙酯(EMS)和甲磺酸异丙酯(IMS).应用碘化钠衍生技术,使用PW-5毛细管柱,载气为氮气,ECD检测,程序升温.MMS、EMS和IMS分别在0.03～0.30、0.05～0.50和0.05～0.50 μg/ml浓度范围内线性关系良好,平均回收率分别为63.5％、100.3％和96.2％,最低检测限分别为0.30、0.50和0.50 ng/ml.     

Lung disease and PKCs

The lung offers a rich opportunity for development of therapeutic strategies focused on isozymes of protein kinase C (PKCs). PKCs are important in many cellular responses in the lung, and existing therapies for pulmonary disorders are inadequate. The lung poses unique challenges as it interfaces with air and blood, contains a pulmonary and systemic circulation, and consists of many cell types. Key structures are bronchial and pulmonary vessels, branching airways, and distal air sacs defined by alveolar walls containing capillaries and interstitial space. The cellular composition of each vessel, airway, and alveolar wall is heterogeneous. Injurious environmental stimuli signal through PKCs and cause a variety of disorders. Edema formation and pulmonary hypertension (PHTN) result from derangements in endothelial, smooth muscle (SM), and/or adventitial fibroblast cell phenotype. Asthma, chronic obstructive pulmonary disease (COPD), and lung cancer are characterized by distinctive pathological changes in airway epithelial, SM, and mucous-generating cells. Acute and chronic pneumonitis and fibrosis occur in the alveolar space and interstitium with type 2 pneumocytes and interstitial fibroblasts/myofibroblasts playing a prominent role. At each site, inflammatory, immune, and vascular progenitor cells contribute to the injury and repair process. Many strategies have been used to investigate PKCs in lung injury. Isolated organ preparations and whole animal studies are powerful approaches especially when genetically engineered mice are used. More analysis of PKC isozymes in normal and diseased human lung tissue and cells is needed to complement this work. Since opposing or counter-regulatory effects of selected PKCs in the same cell or tissue have been found, it may be desirable to target more than one PKC isozyme and potentially in different directions. Because multiple signaling pathways contribute to the key cellular responses important in lung biology, therapeutic strategies targeting PKCs may be more effective if combined with inhibitors of other pathways for additive or synergistic effect. Mechanisms that regulate PKC activity, including phosphorylation and interaction with isozyme-specific binding proteins, are also potential therapeutic targets. Key isotypes of PKC involved in lung pathophysiology are summarized and current and evolving therapeutic approaches to target them are identified.